Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $2.6 million.

  • Tarsus Pharmaceuticals' Cash from Financing Activities rose 30093.9% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $144.0 million, marking a year-over-year decrease of 1602.79%. This contributed to the annual value of $154.7 million for FY2024, which is 1880.53% up from last year.
  • Per Tarsus Pharmaceuticals' latest filing, its Cash from Financing Activities stood at $2.6 million for Q3 2025, which was up 30093.9% from $2.0 million recorded in Q2 2025.
  • Over the past 5 years, Tarsus Pharmaceuticals' Cash from Financing Activities peaked at $136.6 million during Q1 2025, and registered a low of -$136000.0 during Q3 2022.
  • In the last 5 years, Tarsus Pharmaceuticals' Cash from Financing Activities had a median value of $2.6 million in 2025 and averaged $27.4 million.
  • The largest annual percentage gain for Tarsus Pharmaceuticals' Cash from Financing Activities in the last 5 years was 747330000.0% (2022), contrasted with its biggest fall of 28133.33% (2022).
  • Quarter analysis of 5 years shows Tarsus Pharmaceuticals' Cash from Financing Activities stood at -$74000.0 in 2021, then surged by 456.76% to $264000.0 in 2022, then skyrocketed by 7384.85% to $19.8 million in 2023, then tumbled by 85.19% to $2.9 million in 2024, then fell by 12.47% to $2.6 million in 2025.
  • Its Cash from Financing Activities was $2.6 million in Q3 2025, compared to $2.0 million in Q2 2025 and $136.6 million in Q1 2025.